We are seriously c
Pro
device can use two-step RT-PCR to
feature

I write now because we are unsure, if we were to produce
deployed, by whom it would be used and who might be willing to purchase it
grateful if you
qu
control for this epid
invaluable as we weigh the risks and benefits of pivoting the co

W
gary

Gary Schoolnik, M.D.
Professor of Medi
Stanford Medical School
At
Stanford
Chief Medical officer
Visby Medic


Linda P.
Professor of
Professor of Medicine,
Columbia Un

Hi, Patty -



Given the nature of [redacted], should we decline the invitation and refer to CDC?

Thanks for your input.

5. If someone [redacted] articles
other than the self isolation [redacted]
time).

Thank you [redacted]
contribute solutions to this health crisis.

With [redacted] regards.
Linda

Linda P. Fried, M.D., M.P.H.
De[redacted]
Professor of Epidemiology
Mailman School of Public [redacted]
Professor of Medicine [redacted] os College
Senior Vice President for [redacted] Irving IV[redacted]dical Center
Columbia University

- Anne Schuchat will give a brief overview of [illegible] and n
issues.
- Anthony Fauci will give a brief explanation of our understanding of the
virus and development of countermeasures.
- Brig Gen. Paul F[illegible]
protection.
- Acting Chief of Staff Mulvaney will open the floor for questions and
moderate the proceeding[illegible] possible that White House [illegible]
stand in here (Eric U[illegible]land or Mike McKenna).

Expecte[illegible]

Members (Confirmed RSVPs thus far)
Senator James Risch
Leader McCarthy
Rep. Kay Granger
Rep. Greg Walden
Rep. Nita Lowey

Briefers
DHS – Alex Zem[illegible]
CDC—Dr. Anne Schuchat
NIAID—Dr. [illegible] Fauci
ASPR—Dr. Bob Kadlec
FDA—Dr. Steve Hahn
DHS - Ke[illegible]
NSC – Anthony [illegible]
NSC – Matt Pottinger
State – Stephen Bi[illegible]
DOD – [illegible]

NIH-001935

Draft Agenda

1:30-2:00 pm – Opening Keynote

Dr. Anthony Fauci, M.D., NIAID

Introduction: Stephen Morrison, CSIS Global Health Policy Center

2:00-2:50 pm – Panel Discussion

[The economics/business] Joyce Chang, JP Morgan *(confirmed)*

[The politics] Jude Blanchette, CSIS Freeman Chair in China Studies *(confirmed)*

[The foreign politics] Melanie Hart, Center for American Progress *(to be invited)*, or Bonnie Glaser, CSIS China Power Project

[The public health] Yanzhong Huang, Council on Foreign Relations *(confirmed)*

Moderator: Stephen Morrison, CSIS Global Health Policy Center

2:50-3:30 pm – Newsmaker Speech

Matt Pottinger, NSC *(to be invited)*

Moderator and Follow-up Interview: Bonnie Glaser, CSIS China Power Project

J. Stephen Morrison
Senior Vice President & Director, Global Health Policy Center
Center for Strategic and International Studies (CSIS)
1616 Rhode Island Ave. NW
Washington D.C. 20036
(202) 775-3242

but not in Vancouver--the [redacted] one pretty quickly.

To me, one important aspect is the control of respiratory transmission in the hospital [redacted] negative pressure rooms, as for TB [redacted]

(Treating patients with [redacted])

In the community, standard public health quarantine, contact tracing should be sufficient for starters.

[redacted] infections is likely much higher. The 41 deaths are the tip of the iceberg of not 800 infections (5% fatality rate). Although that rate is much better, if the mutating incoming virus becomes very contagious—then the impact [redacted] containment is so important [redacted] government [redacted] doing the right thing.

When a new pathogen arrives, children often have mild disease but they are important [redacted] for transmission in the community, [redacted] household. [redacted] transmission. This [redacted] be even more relevant for 2019-nCoV. It is [redacted] the SOX, but it may [redacted] time point comes.

Happy to help, any way that I can. Thank you for all you and NIAID are doing!!!

Best wishes , Marty

· « …On the mechanism of action, even though the gastric H+/K+-ATP[illegible] exposure to esomeprazole acidified the cytosol and [illegible] eso[illegible] mechanism of action: acutely, it induced intracellular acidification in an ATP12A-independent manner but, chronic exposure, which importantly did not have any deleterious effect on epithelial integrity, was linked to decreased ATP12A mRNA levels. These results open [illegible] as a new therapeutic approach for treating CF lung disease… » (15)

· « …[illegible] gastric H+/K+-ATPase, ATP4A mRNA, which translates to around 85% identity in the protein products… » (15)

· « Proton pump inhibitor therapy predisposes to increased risk of developing pneumonia » (16)

· « Na+/H+ Exchangers Are Required for the Development and Function of [illegible] (17)

· « ATP4a is required for [illegible] to study [illegible] (18)

Regarding coronaviruses and Golgi complex:

· « …Coronaviruses [illegible] compartment (…), also called the cis-Golgi network (…). The three main envelope proteins (S, M and E) are synthesized [illegible] and move [illegible] with the viral nucleocapsid (…). Once virions have budded into the lumen of the ERGIC, the ~120 nm particles must move through the host secretory pathway finally to be released from infected cells. Coronaviruses are believed to follow the constitutive secretory pathway for exocytosis. Although only a few studies have addressed the release of [illegible] during infection, a progressive disruption of the Golgi complex was observed late in infection… »
« …Weak bases (which disrupt acidification), v-ATPase inhibitors, and overexpression of a pH activated K+ channel all block a number of membrane [illegible] trafficking involves a subunit of the membrane sector of the v-ATPase, which has been shown to accumulate in endosomes. This subunit undergoes a conformational change as the luminal pH drops, which recruits cytoplasmic machinery leading to subsequent vesicle formation… » (19)

· « …Pharmacological and other manipulations of [illegible] have all been shown to cause slow trafficking of cargo through the Golgi complex as well as alteration in Golgi morphology…
« …Similar to M2, the infectious bronchitis virus (IBV) coronavirus E protein localizes to multiple secretory pathway disruption [illegible] overexpressed in mammalian [illegible] (…)

· « …The envelope protein [illegible] important role in virus assembly (…) Using coronavirus infectious clones, it was shown that the transmissible gastroenteritis virus E protein is essential for production, and murine [illegible] virus lacking E protein [illegible]
« …The exact mechanism of coronavirus release after budding into the [illegible] compartment is not known [illegible] route to the plasma membrane where fusion of the vacuole results [illegible]

· « …It might be worth investigating whether ion-channel inhibitors, such as amantadine, or proton-pump inhibitors [illegible] whether CoV release is mediated by viroporin ion channel activity or through PPIs with host proteins of the secretory pathway… » (22)

· « [illegible] also important for transportation of newly synthesized acid hydrolases from Golgi to lysosomes » (24)

· «...cardiotonic steroids oual
ATPase, inhibited infection of cells
but not IAV, when the compounds were present duri
entry of MHV at an early stage, resultin
in reduced fusion. In agreement with an early block in infection, the inhibition of V
by low-p
antiviral effect of ouabain could be relieved by the ad
si

In conclusion, in order to verify the possible efficacy of omeprazole and esomeprazo
corona

· The
and teste
Unlike an in vitro test, the human body is a
ionized form
transport.
But the transf
reactions
fo

· As omeprazole can modify or eve
level (26), based on a computer simulatio
omeprazole wi
absence of data clearly
omeprazole after being in contact (at a distance of less than 2 to 3 m
had th
of coronav
processes.
This
immune system a complementary optic

· Personal exp
reminds me of the indication to divide the daily dose into two daily doses (ome
usual
inflammat
in the context of the cor

· share the maxi
people at risk of contaminatio

· divi

· take the daily dose of o
condition

· to resume the daily dose of omeprazole in two daily doses when the symptoms of severity diminish.

The effectiveness of esc

Taking into account the aforementioned [illegible] that omeprazole will re[illegible] secretion [illegible] respiratory [illegible] [illegible]come negative (by modifying the pH, the ciliary mobility and the volume [illegible] prolonged use, thus promoting the risk of bacterial pneumonia (29).
The advantages an[illegible] depending on the user [illegible] cytochrome P 450 (30).

Best regards

Johannes Hambura

1. Long J, Wright E, Molesti E, Temperton N, Ba[illegible]y W. Antiviral therapies against Ebola and other emerg[illegible] viral diseases using existing medic[illegible] doi:10.12688/f100[illegible]esearch.6[illegible]85.2

2. Dowall SD, Bewley K, Watson RJ, et al. Antiviral Screening [illegible] Multiple Compounds against Ebola Virus. Viruses. 2016;8(11):277. Published 2016 Oct 27. [illegible]

3. [illegible] Pharmacokineti[illegible] pharmac[illegible] Ne[illegible]

4. Spugnini EP, Ci[illegible] G, Fais S. Proton pump [illegible] strategy. J Exp Clin Cancer Res. 2010;29(1):44. Published 2010 May 8. doi:10.1186/1756-99[illegible]

5. Sasaki T, Yamaya M, Ya[illegible] [illegible]shimura H, Sasaki H. The proton pump inhibitor lansopr[illegible] tracheal epithelial cells. Eur J Pharmacol. 2005;14:201–210. doi: 10.1016/j.ejphar.2004.12.042.

6. Gasparini R, [illegible] et al. Do the omeprazole family compounds exert a protective effect [illegible] influenza-like illness?. BMC Infect Dis. 2014;14:297. [illegible] 2014 Jun 2. doi:10.1186/1471-2334-14-297

7. Moormann AEBDP, F[illegible] antiviral agent[illegible] United States1999 Jun. 14, 200[illegible]

8. Kikuchi S, Naoki Y, Tajiri T, Wa[illegible] N. Proton pump inhibitors for chronic obstructive pulm[illegible] Cochrane Da[illegible] Syst Rev. 2018;2018(8):CD013113. Published 2018 Aug 3[illegible] doi:10.1[illegible]

9. M[illegible] N, Pestov N, Adams G[illegible] Geering K. Nongastric H,K-ATPase: structure and functional properties. Ann N Y Acad Sci. 2003 Ap[illegible]

10. Matsui MS, [illegible] Omeprazole a[illegible] ATP7A trafficking. J Invest Dermatol. [illegible] Mar; 135(3):834-841.

11. De Milito A, [illegible] Venturi G, Lozupone F, [illegible] M[illegible] [illegible]do F, Rivoltini L, Fais S. pH-dep[illegible] inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2009.

12. Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibitors enhance the effects of cytot[illegible] agents in chemoresistant epithelial ovarian carcinoma. Oncotarget. 2015;6(33):35040–35050. doi:10.18632/oncotarget.5319

13. La[illegible]

P
30.

Let me kn

Thanks,

Joslyn
Editor
WTOP News
(2

period of f
treat

I cannot
and

your insigh

Sincerely,

Ching Y. V

Your partici[illegible] avail[illegible]
an invit[illegible]
questions about the event or yo[illegible]
invitation.

Best wishes,

Richard

Richard Fon[illegible]
Executive Dire[illegible]
Trilateral Commis[illegible]sion -



Thanks,
Jon

Jonathan [illegible] Pook, M.D.
Chief Medical Corresp[illegible] U.S. News &
Professor of Medicine
NYU La[illegible]
Twitter @[illegible]